MedTrace Logo

A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram

NCT01638689 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-07-12

No results posted yet for this study

Summary

Healthy males were examined with positron emission tomography (PET) and the radioligand 11C-AZ10419369, before and after administration of a single dose escitalopram. A change in the binding potential of 11C-AZ10419369 between the baseline and the post-dose condition was hypothesized to reflect a change in serotonin concentration.

Conditions

  • Healthy

Interventions

DRUG

Escitalopram

20 mg p.o.

Sponsors & Collaborators

Principal Investigators

  • Magdalena Nord, MD · Karolinska Institutet

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-02-28
Completion
2012-07-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01638689 on ClinicalTrials.gov